The FHN trial of 6-times versus 3-times a week in-center dialysis was famously a modestly positive trial. It was not powered to show a mortality benefit and as expected, it did not show a mortality benefit. This year at Kidney Week, Chertow and the FHN Team presented a poster with subsequent follow-up of the randomized patients. While almost all of the patient migrated back to conventional 3-days a week dialysis after the trial, they found that patients randomized to daily in-center hemodialysis have had a better survival than patients randomized to 3-times a week dialysis. The Hazard ratio was a healthy 0.54!
How did this not get an oral presentation?
You can find it on page 442 of the 2013 abstract supplement, which you can download here.
 |
| You may or may not see this in #NephMadness |